New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Credit: IDIBELL-Bellvitge Biomedical Research Institute

Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around the world, including nine in Spain, to which the team of Dr. Daniel Podzamczer of the Bellvitge University hospital (HUB) has contributed. The results of the trial, published in The Lancet, pave the way to the implantation of all-injectable antiretroviral therapies with a lower frequency of administration, which would imply a significant improvement of the quality of life of HIV patients.

In the study, which involved 286 patients with previously suppressed viral loads, researchers tested the effectiveness of the combination of the inegrase inhibitor carbotegravir and rilpivirine, a non-nucleoside , injected intramuscularly every four or eight weeks. This combination was compared to standard maintenance therapy, which includes three orally administered drugs: carbotegravir, abacavir and lamivudine.

"This is the first time that all-injectable ART has been used in a trial," says Dr. Podzamczer. "In addition, it consists of only two drugs, which supports the paradigm shift of three to two drugs in some virologically suppressed patients." The injected drugs are nanoparticles with a longer half-life of several weeks.

After 96 weeks, researchers found that 87 percent of patients in the group treated every four weeks and 94 percent in the group treated every eight weeks maintained viral load suppression, greater than the standard oral treatment group at 84 percent.

"With HIV, we are at a point of chronification of the disease; in a few years, we have moved from giving 14 pills a day to one or two, but it is still a daily treatment that requires strict compliance. Therefore, spacing administration to once every month or every two months will potentially translate into improved adherence rates and improved quality of life for patients," explains Dr. Podzamczer.

At the same time, the levels of satisfaction of the participating patients were also evaluated; at the end of the trial, about 90 percent of in the groups treated intramuscularly were very satisfied with the idea of continuing with this type of treatment. Currently, participating centers and research teams are already working on the development of a new Phase III clinical trial that corroborates the results in terms of efficacy, safety and tolerability for both injectable treatments, every four and every eight weeks.

Explore further: Meds by monthly injection might revolutionize HIV care (Update)

More information: David A Margolis et al, Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial, The Lancet (2017). DOI: 10.1016/S0140-6736(17)31917-7

Related Stories

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Improved survival with enhanced prophylaxis plus ART in HIV

July 20, 2017
(HealthDay)—For patients with advanced HIV who are initiating antiretroviral therapy (ART), enhanced prophylaxis is associated with reduced rates of death at 24 and 48 weeks, according to a study published in the July 20 ...

Shorter treatment course potentially on the horizon for hep C patients

April 15, 2016
Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in ...

New antiretroviral drugs decrease chances of HIV sexual transmission

November 22, 2016
More than 2 million people were infected by human immunodeficiency virus (HIV) in 2015 via sexual transmission. Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Daniel Podzamczer, have evaluated ...

HIV: A therapeutic advance for resource-limited settings

May 29, 2017
ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa (Cameroon, Burkina Faso, and Senegal), shows that dual therapy with lamivudine and a boosted protease inhibitor is effective ...

New combo pill offers hope to hepatitis C patients who fail other treatment

June 1, 2017
(HealthDay)—A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report.

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.